Osteoclast differentiation inhibitors: A patent review (2008-2012)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 12, 2013, Pages 1591-1610

  Kim, Seong Hwan ^a   Moon, Seong Hee ^a,b  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

ALX 0141; Bone loss; Cilengitide; DW 1350; Osteoclast differentiation; Patent; Sagopilone

Indexed keywords

ABD 295; ABD 455; ABD 456; ABD 599; ABD 773; ABD 781; ABD 789; ALX 0141; BENZAMIDINE DERIVATIVE; BIOLOGICAL PRODUCT; BISPHOSPHONIC ACID DERIVATIVE; BPS 804; CATHEPSIN K INHIBITOR; CILENGITIDE; CYSTATIN C; CYSTEINYL PROTEINASE INHIBITOR; D PINITOL; DIPROPHYLLINE; DW 1350; FURO[3,2 B]PYROL DERIVATIVE; HERBACEOUS AGENT; HU 639; HYBRID PROTEIN; INDENONE DERIVATIVE; MIGLUSTAT; MOR 09281; NSC 707544; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION INHIBITOR; PEPTIDE DERIVATIVE; PROMETHAZINE; PYRAZOLE DERIVATIVE; RAPAMYCIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B INHIBITOR; SAGOPILONE; SULFONAMIDE; TETRAHYDROFURO[3,2 B]PYRROL 3 ONE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE PHASE RESPONSE; AUTOIMMUNE DISEASE; AUTOPHAGY; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CELL DIFFERENTIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INFLAMMATION; JAW OSTEONECROSIS; MALIGNANT NEOPLASTIC DISEASE; MEDICINAL PLANT; METASTATIC MELANOMA; MOLECULAR BIOLOGY; MUSCULOSKELETAL PAIN; NEPHROTOXICITY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PAGET BONE DISEASE; PATENT; PEPTIC ULCER; PERIODONTAL DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SAURURUS CHINENSIS; SCUTELLARIA BAICALENSIS; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; BONE DISEASES; CELL DIFFERENTIATION; DRUG DESIGN; FRACTURES, BONE; HUMANS; MACROPHAGES; MONOCYTES; OSTEOCLASTS; PATENTS AS TOPIC;

EID: 84890072717     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.842556     Document Type: Review

References (122)

1. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42
3. Akiyama T, Dass CR, Choong PF. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 2008;7:3461-9
4. Kajiya M, Giro G, Taubman MA, et al. Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease. J Oral Microbiol 2010;2:doi: 10.3402/jom.v2i0.5532
5. Lippuner K, von Overbeck J, Perrelet R, et al. Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporos Int 1997;7:414-25
6. Muto A, Mizoguchi T, Udagawa N, et al. Lineage-committed osteoclast precursors circulate in blood and settle down into bone. J Bone Miner Res 2011;26:2978-90
7. Grigoriadis AE, Wang ZQ, Cecchini MG, et al. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994;266:443-8
8. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901
9. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007;40:251-64
10. Broadhead ML, Clark JC, Dass CR, et al. Therapeutic targeting of osteoclast function and pathways. Expert Opin Ther Targets 2011;15:169-81
11. Takayanagi H. Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292-304
12. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
13. Kikuta J, Ishii M. Osteoclast migration, differentiation and function: Novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford) 2013;52:226-34
14. Katholieke Universiteit Leuven. Osteoclast activity. WO2012061907; 2012
15. Hall TJ, Schaueblin M. Promethazine inhibits osteoclastic bone resorption in vitro. Calcif Tissue Int 1994;55:68-70
16. Yamamoto T, Hinoi E, Fujita H, et al. The natural polyamines spermidine and spermine prevent bone loss through preferential disruption of osteoclastic activation in ovariectomized mice. Br J Pharmacol 2012;166:1084-96
17. University of Oxford. Agents for inhibiting osteoclastogenesis and/or osteoclast activation. WO2011070407; 2011
18. Butters TD, Dwek RA, Platt FM. Inhibition of glycosphingolipid biosynthesis: Application to lysosomal storage disorders. Chem Rev 2000;100:4683-96
19. Fukumoto S, Iwamoto T, Sakai E, et al. Current topics in pharmacological research on bone metabolism: Osteoclast differentiation regulated by glycosphingolipids. J Pharmacol Sci 2006;100:195-200
20. De Leenheer E, Mueller GS, Vanderkerken K, et al. Evidence of a role for RANKL in the development of myeloma bone disease. Curr Opin Pharmacol 2004;4:340-6
21. Pastores GM, Elstein D, Hrebícek M, et al. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: A pooled analysis of three multinational, open-label studies. Clin Ther 2007;29:1645-54
22. University of Alberta. Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof. WO2011045668; 2011
23. Karsdal MA, Sondergaard BC, Arnold M, et al. Calcitonin affects both bone and cartilage: A dual action treatment for osteoarthritis? Ann NY Acad Sci 2007;1117:181-95
24. Naot D, Cornish J. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone 2008;43:813-18
25. Bhandari KH, Newa M, Chapman J, et al. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats. J Control Release 2012;158:44-52
26. Bhandari KH, Newa M, Uludag H, et al. Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin. Int J Pharm 2010;394:26-34
27. Korea Research Institute of Chemical Technology. Indenone derivative and pharmaceutical composition comprising same. WO2011030955; 2011
28. Lerner UH, Johansson L, Ranjso M, et al. Cystatin C, and inhibitor of bone resorption produced by osteoblasts. Acta Physiol Scand 1997;161:81-92
29. Stralberg F, Henning P, Gjertsson I, et al. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling. FASEB J 2013;27:2687-701
30. Johansson L, Grubb A, Abrahamson M, et al. A peptidyl derivative structurally based on the inhibitory center of cystatin C inhibits bone resorption in vitro. Bone 2000;26:451-9
31. Neobiotics AB. Novel peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation. WO2010147547;2010
32. University of Aberdeen. Biphenyl-4-ylsulfonic acid arylamides and their use as therapeutic agents. WO2008114022; 2008
33. Pimco 2664 Ltd. Aryl-phenylsulfonamido- cycloalkyl compounds and their use. WO2010032009; 2010
34. Pimco 2664 Ltd. Aryl-phenylsulfonamide- phenylene compounds and their use. WO2010032010; 2010
35. Greig IR, Idris AI, Ralston SH, et al. Development and characterization of biphenylsulfonamides as novel inhibitors of bone resorption. J Med Chem 2006;49:7487-92
36. The University Court of the University of Aberdeen. Aryl alkyl sulfonamides as therapeutic agents for the treatment of bone conditions. WO2005118528; 2005
37. Yang P, Wang L, Feng R, et al. Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: Discovery, optimization, and biological evaluation. J Med Chem 2013;56:2045-58
38. Dong-Wha Pharmaceuticals Industry Co. Ltd. Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteoporosis comprising the same. WO2009017346; 2009
39. Dong-Wha Pharmaceuticals Industry Co. Ltd. A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate. WO2010013975; 2010
40. Fleisch H. Bisphosphonates in osteoporosis. Eur Spine J 2003;12(Suppl 2):S142-6
41. Papapetrou PD. Bisphosphonate-Associated adverse events. Hormones (Athens) 2009;8:96-110
42. Binkley N, Krueger D. Combination therapy for osteoporosis: Considerations and controversy. Curr Osteoporos Rep 2005;3:150-4
43. Cusano NE, Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis. Endocrinol Metab Clin North Am 2012;41:643-54
44. Dong-Wha Pharmaceuticals Industry Co. Ltd. A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt. WO2010013969; 2010
45. Garcia C, Boyce BF, Gilles J, et al. Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J Bone Miner Res 1996;11:1619-27
46. Hikiji H, Ishii S, Yokomizo T, et al. A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc Natl Acad Sci USA 2009;106:21294-9
47. Ren W, Dziak R. Effects of leukotrienes on osteoblastic cell proliferation. Calcif Tissue Int 1991;49:197-201
48. Traianedes K, Dallas MR, Garrett IR, et al. 5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology 1998;139:3178-84
49. Yissum Research Development Co. Fatty acid amides and uses thereof. WO2009125409; 2009
50. Smoum R, Bar A, Tan B, et al. Oleoyl serine, an endogenous N-Acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci USA 2010;107:17710-15
51. Bab I, Smoum R, Bradshaw H, et al. Skeletal lipidomics: Regulation of bone metabolism by fatty acid amide family. Br J Pharmacol 2011;163:1441-6
52. Ewha Womans University. Composition comprising pyrazole derivatives for preventing or treating osteoporosis. WO2009119987; 2009
53. Quinn MT, Schepetkin IA. Role of NADPH oxidase in formation and function of multinucleated giant cells. J Innate Immun 2009;1(6):509-26
54. Barrett AJ, Rawlings ND. Evolutionary lines of cysteine peptidases. Biol Chem 2001;382:727-33
55. Amura Therapeutics Ltd. Furo[3,2-b] pyrrol derivatives. WO2008007103; 2008
56. Amura Therapeutics Ltd. Furo[3,2-b] pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors. WO2008007109; 2008
57. Amura Therapeutics Ltd. Tetrahydrofuro [3,2-b]pyrrol-3-ones as cathepsin K inhibitors. WO2008007114; 2008
58. Amura Therapeutics Ltd. Furo[3,2-b] pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors. WO2008007130; 2008
59. Ishikawa T, Kamiyama M, Tani-Ishii N, et al. Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides. Mol Carcinog 2001;32:84-91
60. Korea Institute of Oriental Medicine. Composition for preventing or treating osteoporosis, containing Ssangwhatang or lactobacillus fermented product thereof. WO2011162523; 2011
61. Choi SW, Moon SH, Yang HJ, et al. Antiresorptive activity of bacillus-fermented antler extracts: Inhibition of osteoclast differentiation. Evid Based Complement Alternat Med 2013;2013:748687
62. Shim KS, Lee JH, Ma CJ, et al. Inhibitory effect of Ssanghwa-Tang on bone loss in ovariectomized rats. Anim Cells Syst 2010;14:283-9
63. Shim KS, Lee JH, Lee JH, et al. Effect of Ssangwha-Tang fermented by Lactobacillus fermentum on osteoclast differentiation and osteoporosis of ovariectomized rats. Korean J Oriental Med 2010;16:149-55
64. Hou GQ, Guo C, Song GH, et al. Lipopolysaccharide (LPS) promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells. Int J Mol Med 2013; Epub ahead of print
65. BRNSCIENCE Co., Ltd. Composition for preventing and treating bone diseases, containing medicinal herb extracts as active ingredient. WO2011034223; 2011
66. Korea Research Institute of Chemical Technology & Korea Food Research Institute. Composition for the prevention or treatment of osteoporosis, containing a mixture of Saururus chinensis and Scutellaria baicalensis extracts as an active ingredient. WO2010008150; 2010
67. Sung MJ, Davaatseren M, Hur HJ, et al. Antiosteoporotic activity of Saururus chinensis extract in ovariectomized rats. Phytother Res 2012;26:1182-8
68. Kim MH, Ryu SY, Choi JS, et al. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. J Cell Physiol 2009;221:618-28
69. Kim SN, Kim MH, Kim YS, et al. Inhibitory effect of (-)-saucerneol on osteoclast differentiation and bone pit formation. Phytother Res 2009;23:185-91
70. Kim MH, Ryu SY, Bae MA, et al. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis. Food Chem Toxicol 2008;46:3375-82
71. Chungnam National University & Solent Co. Ltd. Composition for prevention or treatment of bone metabolism disorder comprising D-pinitol as an active ingredient. WO2009031819; 2009
72. Liu SC, Chuang SM, Tang CH. D-pinitol inhibits RANKL-induced osteoclastogenesis. Int Immunopharmacol 2012;12:494-500
73. Bayer Schering Pharma AG. Use of epothilones in the treatment of osteoporosis and related diseases. WO2008068043; 2008
74. Heinz DW, Schubert WD, Hofle G. Much anticipated-The bioactive conformation of epothilone and its binding to tubulin. Angew Chem Int Ed Engl 2005;44:1298-301
75. Strube A, Suominen MI, Rissanen JP, et al. The anti-Tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo. Osteoporos Int 2011;22:2887-93
76. Ferrandina G, Mariani M, Andreoli M, et al. Novel drugs targeting microtubules: The role of epothilones. Curr Pharm Des 2012;18:2793-803
77. Nordic Bioscience A/S. Diphyllin and other lignans as a medicament for V-ATPase mediated disease. WO2008058897; 2008
78. Qin A, Cheng TS, Pavlos NJ, et al. V-ATPases in osteoclasts: Structure, function and potential inhibitors of bone resorption. Int J Biochem Cell Biol 2012;44:1422-35
79. Li YP, Chen W, Liang Y, et al. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 1999;23:447-51
80. Taranta A, Migliaccio S, Recchia I, et al. Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. Am J Pathol 2003;162:57-68
81. Sørensen MG, Henriksen K, Neutzsky-Wulff AV, et al. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res 2007;22:1640-8
82. Ablynx NV. Inhibition of bone resorption with RANKL binding peptides. WO2012163887; 2012
83. Dempster DW, Lambing CL, Kostenuik PJ, et al. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: A review of preclinical and clinical data. Clin Ther 2012;34:521-36
84. Rahbarizadeh F, Ahmadvand D, Sharifzadeh Z. Nanobody; an old concept and new vehicle for immunotargeting. Immunol Invest 2011;40:299-338
85. Holz JB. Safety, pharmacokinetics and efficacy of anti-RANKL- Nanobody ALX-0141 in healthy postmenopausal women. EULAR; London: 2011
86. Jitsubo Co. Ltd. & Tokyo Medical and Dental University. Pharmaceutical composition that uses novel peptide that mimics TNF receptor loop peptide containing cross-linked structure. WO2012121058; 2012
87. Kojima T, Aoki K, Nonaka K, et al. Subcutaneous injections of a TNF-Alpha antagonistic peptide inhibit both inflammation and bone resorption in collagen-induced murine arthritis. J Med Dent Sci 2005;52:91-9
88. Saito H, Kojima T, Takahashi M, et al. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-Tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis Rheum 2007;56:1164-74
89. Azuma Y, Kaji K, Katogi R, et al. Tumor necrosis factor-Alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858-64
90. Nakao A, Fukushima H, Kajiya H, et al. RANKL-stimulated TNFalpha production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways. Biochem Biophys Res Commun 2007;357:945-50
91. Kim N, Kadono Y, Takami M, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005;202:589-95
92. Tokyo Women's Medical University. Inhibitor of osteoclast formation containing anti-VDAC antibody. WO2012050154; 2012
93. Kotake S, Yago T, Kawamoto M, et al. Voltage-dependent anion channels (VDACs, porin) expressed in the plasma membrane regulate the differentiation and function of human osteoclasts. Cell Biol Int 2013;37:65-77
94. Daiichi Sankyo Co., Ltd. Antibody targeting osteoclast-related protein Siglec-15. WO2012045481; 2012
95. Alethia Biotherapeutics, Inc. Siglec 15 antibodies in treating bone loss-related disease. WO2011041894; 2011
96. Takahata M, Iwasaki N, Nakagawa H, et al. Sialylation of cell surface glycoconjugates is essential for osteoclastogenesis. Bone 2007;41:77-86
97. Alethia Biotherapeutics, Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling. WO2007093042; 2007
98. Hiruma Y, Hirai T, Tsuda E. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation. Biochem Biophys Res Commun 2011;409:424-9
99. Hiruma Y, Tsuda E, Maeda N, et al. Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice. Bone 2013;53:87-93
100. Kameda Y, Takahata M, Komatsu M, et al. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3- kinase/Akt and Erk pathways in association with signaling adaptor DAP12. J Bone Miner Res 2013;doi:10.1002/jbmr.1989
101. Dechantsreiter MA, Planker E, Mathä B, et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V) beta(3) integrin antagonists. J Med Chem 1999;42:3033-40
102. Merck Patent GmbH. Peptide for use in the treatment of breast cancer and/or bone metastases. WO2012007137; 2012
103. Max R, Gerritsen RR, Nooijen PT, et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-Associated vessels of human carcinomas. Int J Cancer 1997;71(3):320-4
104. Nemeth JA, Cher ML, Zhou Z, et al. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003;20:413-20
105. Inoue M, Ross FP, Erdmann JM, et al. Tumor necrosis factor alpha regulates alpha(v)beta5 integrin expression by osteoclast precursors in vitro and in vivo. Endocrinology 2000;141:284-90
106. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-Targeting arginine-glycine-Aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610-17
107. Kim KB, Prieto V, Joseph RW, et al. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res 2012;22:294-301
108. Sungkyunkwan University. Peptide for inhibiting interaction between RANKL and RANK, and pharmaceutical composition containing same. WO2011149310; 2011
109. Ta HM, Nguyen GT, Jin HM, et al. Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc Natl Acad Sci USA 2010;107:20281-6
110. Yagi M, Miyamoto T, Sawatani Y, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005;202:345-51
111. Zeng Z, Zhang C, Chen J. Lentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts. J Bone Miner Metab 2013; [Epub ahead of print]
112. University of Rochester. DC-STAMP antibodies. WO2010127180; 2010
113. Chiu YH, Mensah KA, Schwarz EM, et al. Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res 2012;27:79-92
114. Erlebacher A, Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 1996;132:195-210
115. Sells Galvin RJ, Gatlin CL, Horn JW, et al. TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun 1999;265:233-9
116. The Vanderbilt University. Anti-TGF-beta induction of bone cell function and bone growth. WO2010124276; 2010
117. Edwards JR, Nyman JS, Lwin ST, et al. Inhibition of TGF-b signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res 2010;25:2419-26
118. Shanghai Fuchunkexin Biotech Co. Ltd. Fusion protein inhibiting osteoclast formation, preparation method and drug compositions thereof. WO2010043153; 2010
119. Shanghai Kexin Biotech Co. Ltd. Fusion protein inhibiting osteoclast formation, preparation method and medicine compositions thereof. US20110243944; 2011
120. Barrow AD, Trowsdale J. You say ITAM and I say ITIM, let's call the whole thing off: The ambiguity of immunoreceptor signalling. Eur J Immunol 2006;36:1646-53
121. Sungkyunkwan University. Peptide inhibitors of receptor activator of NF-kappaB, and pharmaceutical composition including the same. WO2008127066; 2008
122. Taubman MA, Valverde P, Han X, et al. Immune response: The key to bone resorption in periodontal disease. J Periodontol 2005;76:2033-41